NOVN Novan Inc

Scott+Scott, Attorneys at Law, LLP Reminds Investors of Securities Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline of January 2

Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, reminds investors that a class action lawsuit is pending against Novan, Inc. (NASDAQ: NOVN) (“Novan” or the “Company”) and other defendants, related to alleged violations of federal securities laws. If you purchased Novan common stock in or traceable to the Company’s initial public offering (“IPO”), on or about September 26, 2016, or if you purchased stock between September 26, 2016 and January 26, 2017 you are encouraged to contact a Scott+Scott attorney at (844) 818-6980 for additional information.

Novan is a drug development company that focuses on the development and commercialization of nitric oxide-based therapies in dermatology. At all relevant times, Novan’s lead product candidate was SB204, a once-daily topical gel for the treatment of acne vulgaris.

The lawsuit claims materially false and misleading statements were made regarding Novan’s business and outlook, specifically regarding SB204.

On January 27, 2017, Novan announced top-line results of the Company’s two Phase 3 clinical trials of SB204, advising investors that the drug had met its goals in only one of the studies. On this news, Novan’s share price fell $13.84, more than 74%, to close at $4.86 on January 27.

On June 5, 2017, Novan announced that it was replacing its Chief Executive Officer, Nathan Stasko, laying off 20% of its workforce, and executing a plan to turn its focus to earlier-stage compounds. On this news, Novan’s share price fell $0.22, or 4.53%, to close at $4.64 on June 5.

Additional disclosures on August 2, 2017 revealed that Novan was retreating further from SB204, causing the stock to drop more than 17% to close at $4.54 that day.

What You Can Do

If you purchased Novan stock between September 26, 2016 and January 26, 2017, inclusive, or if you have questions about this notice or your legal rights, please contact attorney Rhiana Swartz at (844) 818-6980, or at [email protected]. Investors have until January 2, 2018, to move for lead plaintiff.

About Scott+Scott, Attorneys at Law, LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

EN
14/12/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novan Inc

 PRESS RELEASE

Novan Enters into Agreement to Sell Substantially All of its Assets, i...

Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection – The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) continues, with Pre-Approval Inspection (PAI) complete and favorable mid-cycle review communication from FDA – – A...

 PRESS RELEASE

Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockh...

Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6, 2023 at 9:30 a.m. Eastern Time in a virtual format. The Company also announced that its Chairman, President and CEO, Paula Brown Stafford, will provide a corporate update on the Company after the conclusion of the ASM, including the Company’s current focus, position...

 PRESS RELEASE

Novan Focuses Strategic Direction and Announces Restructuring

Novan Focuses Strategic Direction and Announces Restructuring – Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% – DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that following an evaluation of its commercial and developmental stage assets, it has decided to ...

 PRESS RELEASE

Novan Reports First Quarter 2023 Financial Results and Provides Corpor...

Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update – Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) – – Strong prescription growth across three promoted products – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the first quarter ended March 31, 2023, and provided a corporate update. The Company will host a conference call and webcast, today...

 PRESS RELEASE

Novan to Report First Quarter 2023 Financial Results on May 15, 2023

Novan to Report First Quarter 2023 Financial Results on May 15, 2023 DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day. The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch